CTLA-4 Inhibitors Pipeline Analysis 2024: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight

As per DelveInsight's assessment, globally, CTLA-4 Inhibitors Competitive Landscape constitutes 40+ key companies continuously working towards developing 50+ CTLA-4 inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
(Albany, United States) "CTLA-4 Inhibitors Competitive Landscape Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CTLA-4 inhibitors Market.

The CTLA-4 Inhibitors Competitive Landscape report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for sample report @ [https://www.delveinsight.com/sample-request/ctl-4-inhibitors-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key takeaways from the CTLA-4 Inhibitors Competitive Landscape Report:

* CTLA-4 Inhibitors Companies across the globe are diligently working toward developing novel CTLA-4 inhibitors treatment therapies with a considerable amount of success over the years.
* CTLA-4 inhibitors companies working in the treatment market are Molecular Templates, Shanghai Henlius Biotech, Harbour BioMed, Alpine Immune Sciences, Agenus, Xencor, Innovent Biologics, Alphamab Oncology, Bristol-Myers Squibb, Akeso Biopharma, and others, are developing therapies for the CTLA-4 inhibitors treatment

* Emerging CTLA-4 inhibitors therapies in the different phases of clinical trials are- MT-8421, HLX-13, HBM4003, ALPN-202, Botensilimab, Vudalimab, IBI-310, KN046, Ipilimumab, Cadonilimab, and others are expected to have a significant impact on the CTLA-4 inhibitors market in the coming years.
* In March 2023, Molecular Templates, Inc. obtained approval from the US Food and Drug Administration (FDA) after evaluating its Investigational New Drug Application (IND) to advance clinical trials for its innovative MT-8421 ETB program, which targets CTLA-4 in patients with relapsed/refractory solid tumors previously treated with checkpoint inhibitors. Preclinical findings from MT-8421 revealed that treatment depleted immune suppressive Tregs in the TME but not in the periphery, as observed in a transgenic mouse model expressing human CTLA-4 and harboring syngeneic subcutaneous tumors.
* In March 2023, Agenus initiated a randomized, open-label, Phase II Trial of Nab-paclitaxel +Gemcitabine with or without Botensilimab (AGEN1181) in patients with metastatic pancreatic cancer who have progressedon prior 5FU + Leucovorin + Irinotecan + Oxaliplatin (FOLFIRINOX). This will be a prospective, multicenter, clinical trial ofbotensilimab in combination with nab-paclitaxel + gemcitabine or nab-paclitaxel + gemcitabine alone.
* In February 2023, Akeso Biopharma Co., Ltd., in partnership with Chia Tai Tianqing Pharmaceutical Group Co., Ltd., has launched a clinical trial for Cadonilimab Plus Anlotinib in patients with recurrent, metastatic, or persistent cervical cancer. This trial aims to evaluate the efficacy of a novel treatment regimen comprising cadonilimab and anlotinib. Currently, the trial is actively enrolling participants and is anticipated to conclude by October 2024, with an expected enrollment of 48 participants.
* In October 2022, The FDA greenlit tremelimumab (Imjudo), a CTLA-4 immune checkpoint inhibitor, for use in combination with durvalumab (Imfinzi) as a first-line immunotherapy for unresectable hepatocellular cancer (HCC). This new indication involves administering a single 300 mg priming dose of tremelimumab alongside durvalumab at a dose of 1,500 mg every 4 weeks, known as the STRIDE regimen (single tremelimumab, regular interval durvalumab).
* In August 2022, Biocytogen Pharmaceuticals and TRACON Pharmaceuticals, Inc. revealed that the FDA granted approval for the Investigational New Drug (IND) application, allowing the commencement of a Phase I/II clinical trial for YH001 combined with envafolimab and doxorubicin. This study aims to evaluate the treatment's efficacy in sarcoma patients, including those who have not undergone prior therapy.

CTLA-4 inhibitors Overview

CTLA-4 inhibitors are a class of immunotherapy drugs designed to enhance the body's immune response against cancer. CTLA-4 (Cytotoxic T-Lymphocyte Antigen-4) is a checkpoint protein on T cells, acting as an immune suppressor by downregulating immune responses. Inhibiting CTLA-4 can amplify the immune system's ability to recognize and attack cancer cells.

The most well-known CTLA-4 inhibitor is ipilimumab, approved for the treatment of advanced melanoma and under investigation for other cancers. By blocking CTLA-4, ipilimumab and similar drugs prevent T cells from being turned off, thereby promoting a more robust and sustained immune attack on tumor cells.

CTLA-4 inhibitors have shown significant efficacy in some cancers, leading to prolonged survival in patients with advanced stages of the disease. However, they can also cause a range of immune-related adverse effects, such as colitis, dermatitis, hepatitis, and endocrinopathies, due to increased immune activity against normal tissues.

Management of these side effects involves immunosuppressive treatments like corticosteroids and careful monitoring of patients. Research is ongoing to optimize the use of CTLA-4 inhibitors, including combination therapies with other checkpoint inhibitors like PD-1/PD-L1 inhibitors, which may enhance therapeutic efficacy and reduce adverse effects.

Overall, CTLA-4 inhibitors represent a groundbreaking approach in oncology, offering new hope for patients with difficult-to-treat cancers by harnessing the power of the immune system.

Get a Free Sample PDF Report to know more about CTLA-4 Inhibitors Competitive Landscape Therapeutic Assessment- [https://www.delveinsight.com/report-store/ctl-4-inhibitors-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Emerging CTLA-4 inhibitors Drugs Under Different Phases of Clinical Development Include:

* MT-8421: Molecular Templates
* HLX-13: Shanghai Henlius Biotech
* HBM4003: Harbour BioMed
* ALPN-202: Alpine Immune Sciences
* Botensilimab: Agenus
* Vudalimab: Xencor
* IBI-310: Innovent Biologics
* KN046: Alphamab Oncology
* Ipilimumab: Bristol-Myers Squibb
* Cadonilimab: Akeso Biopharma

CTLA-4 inhibitors Route of Administration

CTLA-4 Inhibitors Competitive Landscape report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical

CTLA-4 inhibitors Molecule Type

CTLA-4 inhibitors Products have been categorized under various Molecule types, such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy

CTLA-4 Inhibitors Competitive Landscape Therapeutics Assessment

* CTLA-4 inhibitors Assessment by Product Type
* CTLA-4 inhibitors By Stage and Product Type
* CTLA-4 inhibitors Assessment by Route of Administration
* CTLA-4 inhibitors By Stage and Route of Administration
* CTLA-4 inhibitors Assessment by Molecule Type
* CTLA-4 inhibitors by Stage and Molecule Type

DelveInsight's CTLA-4 inhibitors Report covers around 50+ products under different phases of clinical development like

* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration

Further CTLA-4 inhibitors product details are provided in the report. Download the CTLA-4 Inhibitors Competitive Landscape report to learn more about the [https://www.delveinsight.com/sample-request/ctl-4-inhibitors-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key companies in the CTLA-4 inhibitors Therapeutics Market include:

Key companies developing therapies for CTLA-4 inhibitors are - Innovent Biologics, Alphamab Oncology, Agenus, Harbour BioMed, AstraZeneca, Alpine Immune Sciences, Henlix Biotech, DotBio, TrueBinding, Ocean Biomedical, Xencor, Molecular Templates, Akeso, Inc., TRACON Pharmaceuticals, Inc., Biocytogen Pharmaceuticals, and others.

CTLA-4 Inhibitors Competitive Landscape Analysis:

The CTLA-4 Inhibitors Competitive Landscape report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of CTLA-4 inhibitors with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CTLA-4 inhibitors Treatment.
* CTLA-4 inhibitors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* CTLA-4 inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the CTLA-4 inhibitors market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about newly launched CTLA-4 inhibitors drugs and therapies @ [https://www.delveinsight.com/sample-request/ctl-4-inhibitors-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

CTLA-4 Inhibitors Competitive Landscape Market Drivers

* Rise in prevalence of Cancer, increased focus on the applications ofImmunotherapy using CTLA-4 inhibitors for oncology settings are some of the important factors that are fueling the CTLA-4 inhibitors Market.

CTLA-4 Inhibitors Competitive Landscape Market Barriers

* However, side-effects associated with the checkpoint inhibitors immunotherapy, high cost associated with the Treatment and other factors are creating obstacles in the CTLA-4 inhibitors Market growth.

Scope of CTLA-4 Inhibitors Competitive Landscape Drug Insight

* Coverage: Global
* Key CTLA-4 inhibitors Companies: Molecular Templates, Shanghai Henlius Biotech, Harbour BioMed, Alpine Immune Sciences, Agenus, Xencor, Innovent Biologics, Alphamab Oncology, Bristol-Myers Squibb, Akeso Biopharma, and others
* Key CTLA-4 inhibitors Therapies: MT-8421, HLX-13, HBM4003, ALPN-202, Botensilimab, Vudalimab, IBI-310, KN046, Ipilimumab, Cadonilimab, and others
* CTLA-4 inhibitors Therapeutic Assessment: CTLA-4 inhibitors current marketed and CTLA-4 inhibitors emerging therapies
* CTLA-4 inhibitors Market Dynamics: CTLA-4 inhibitors market drivers and CTLA-4 inhibitors market barriers

Request for Sample PDF Report for CTLA-4 Inhibitors Competitive Landscape Assessment and clinical trials @ [https://www.delveinsight.com/sample-request/ctl-4-inhibitors-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. CTLA-4 inhibitors Report Introduction

2. CTLA-4 inhibitors Executive Summary

3. CTLA-4 inhibitors Overview

4. CTLA-4 inhibitors- Analytical Perspective In-depth Commercial Assessment

5. CTLA-4 Inhibitors Competitive Landscape Therapeutics

6. CTLA-4 inhibitors Late Stage Products (Phase II/III)

7. CTLA-4 inhibitors Mid Stage Products (Phase II)

8. CTLA-4 inhibitors Early Stage Products (Phase I)

9. CTLA-4 inhibitors Preclinical Stage Products

10. CTLA-4 inhibitors Therapeutics Assessment

11. CTLA-4 inhibitors Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. CTLA-4 inhibitors Key Companies

14. CTLA-4 inhibitors Key Products

15. CTLA-4 inhibitors Unmet Needs

16 . CTLA-4 inhibitors Market Drivers and Barriers

17. CTLA-4 inhibitors Future Perspectives and Conclusion

18. CTLA-4 inhibitors Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ctla4-inhibitors-pipeline-analysis-2024-ema-pdma-fda-approvals-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage



This release was published on openPR.